Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
688235.SS
BUYBeOne Medicines AG · Healthcare · Switzerland · $46.1B · Avg Vol: $242M/d
COMPANY DESCRIPTION
BeOne Medicines is a clinical-stage biotechnology company focused on developing novel oncology therapies and precision medicines. The company's competitive advantage is rooted in its proprietary drug discovery platform targeting specific cancer mutation pathways. It operates as an innovative niche player in the global oncology space, leveraging strategic research collaborations to advance its pipeline.
FINANCIAL SUMMARY (CNY)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.6B | 16.7B | 25.9B | 36.3B | 55.7% | 39.0B | 44.2B | 50.6B | 18.1% |
| EPS (CNY) | -119.24 | -51.96 | -38.41 | 17.01 | — | 2.31 | — | — | — |
| Shares | 115.1M | 115.1M | 115.1M | 115.1M | 0.0% | 115.1M | — | — | — |
| Debt | 4.1B | 6.3B | 7.3B | 7.4B | 22.4% | 13.9B | — | — | — |
| Equity | 29.8B | 24.0B | 22.6B | 29.6B | -0.2% | — | — | — | — |
| Op CF | -10.2B | -7.9B | -954.8M | 7.7B | — | 8.7B | — | — | — |
| Inv CF | 7.3B | 407.4M | -3.7B | -1.9B | — | — | — | — | — |
| Fin CF | -128.8M | 2.8B | 1.3B | 7.2B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 688235.SS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 688235.SS | BeOne Medicines AG(you) | $46.1B | 78 | BUY |
| 0QNO.L | Lonza Group AG | $47.0B | 61 | HOLD |
| 0K10.L | Mettler-Toledo International Inc. | $33.1B | 57 | HOLD |
| BANB.SW | Bachem Holding AG | $6.7B | 52 | HOLD |
| BBZA.DE | BB Biotech AG | $3.1B | 99 | STRONG BUY |
| BSLN.SW | Basilea Pharmaceutica AG | $794M | 84 | STRONG BUY |
| IDIA.SW | Idorsia Ltd | $2.2B | 33 | SELL |
| GALD.SW | GALDERMA GROUP N | $49.5B | 70 | BUY |
| CRSP | CRISPR Therapeutics AG | $4.6B | 14 | STRONG SELL |
| PHVS | Pharvaris N.V. | $2.4B | 26 | SELL |
Peer medians: ROE 10.5% · P/E 23.9x · Gross margin 47.9%